AN2 Therapeutics Inc

NASDAQ:ANTXUnited States

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

Contact Information

Headquarters

1800 El Camino Real, Suite DMENLO PARK, CA, United States 94025-3069

Phone

650-331-9090

Fax

---

Executives

Independent Chairman of the Board

Joseph Zakrzewski

President, Chief Executive Officer, Director

Eric Easom

Co-Founder, Head of Biology

Michael Alley

Chief Financial Officer

Lucy Day

Chief Development Officer

Sanjay Chanda